Non-myeloablative allogeneic stem cell transplantation (also known as mini-transplantation or reduced-intensity conditioning transplantation) is a major advance in the field of hematopoietic transplantation within the last 5 years.
... myeloma: Bologna 96 clinical study. J Clin Oncol 2007;25(17):2434–2441. 154. Mai EK, Benner A, Bertsch U, et al. Single versus tandem high-dose melphalan followed by autologous blood stem cell transplantation in multiple myeloma: long-term ...
... tandem high-dose melphalan followed by autologous blood stem cell transplantation in multiple myeloma: Long-term results from the phase III GMMG-HD2 trial. Br J Haematol 2016;173(5):731–741. 174. Cavo M, Gay FM, Patriarca F, et al. Double ...
... , et al; EBMT Chronic Malignancies Working Party Plasma Cell Disorders Subcommittee. Autologous/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMT- ...
This book titled Contemporary Bone Marrow Transplantation aims to be a reference text comprehensively covering various facets of hematopoietic stem cell transplants with latest insights about the technique and basic sciencebehind it .
... autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma. Blood. 2006;107(9):3474-3480. 425. Moreau ...
This handbook is an in-depth and comprehensive guide to the pathophysiology, diagnosis, staging, treatment and management of patients with multiple myeloma.
... reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long- term ... follow-up of a comparison of nonmyeloablative allografting with autografting for newly diagnosed myeloma. Blood. 2011;117 ...
... versus-host disease is the major predictive factor for response to donor lymphocyte infusions in multiple myeloma. Blood 2004; 103: 4362–4364. 137 Gahrton G, Svensson H, Cavo M, et al. Progress in allogeneic ... autologous stem cell ...
Abstract: Despite significantly improved survival and response rates in patients diagnosed with multiple myeloma, it still remains an incurable disease with a poor outcome, especially in high-risk groups.